Skip to Main Content

Paper Details

Liver tests, cardiovascular outcomes and effects of empagliflozin in patients with heart failure and preserved ejection fraction: The EMPEROR-Preserved trial.
Eur J Heart Fail
3
2023
CVD, EMPagliflozin, Empagliflozin, HFpEF, HHF, N, N-terminal pro-B-type natriuretic peptide, Patients, alanine, alanine aminotransferase, albumin, alkaline phosphatase, aspartate, aspartate aminotransferase, bilirubin, cardiovascular death, chrOnic heaRt Failure, empagliflozin, heart failure, liver disease, liver function abnormalities, patients
Author NameAffiliation
Gerasimos FilippatosNational and Kapodistrian University of Athens School of Medicine, Athens University Hospital Attikon
Milton PackerBaylor University Medical Center
Milton PackerImperial College
  • 1 - 3

Datasets

Release 1.2